Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Investigating the role of myeloperoxidase as a key mediator of renal damage in crescentic glomerulonephritis and renocardiac disease
-
Publication Type:Thesis/Dissertation
-
Authors:Antonelou M
-
Date awarded:28/07/2020
-
Awarding institution:UCL (University College London)
-
Language:English
Abstract
Crescentic glomerulonephritis (CGN) describes a severe form of glomerular
inflammation, which results from various systemic or renal specific diseases,
including anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis
(AAV) characterised by glomerular neutrophil and monocyte activation and
neutrophil extracellular trap deposition. Diseases associated with CGN are
frequently associated with increased cardiovascular disease, which represents
a significant cause of premature mortality. Myeloperoxidase (MPO), a heme
containing peroxidase stored in neutrophils and monocytes, is a key component
of innate immune defence, generating hydrochlorous acid and free radicles that
can also lead to host tissue damage. Additionally, MPO has been shown to
contribute to vascular inflammation and atherosclerosis through oxidation of
lipoproteins and catabolism of nitrous oxide leading to endothelial damage. In
humans, MPO deficiency does not appear to lead to an immunodeficient
phenotype. In this thesis, the role of selective MPO inhibition using AZM198, as
a therapeutic target in CGN and associated reno-cardiac disease is explored.
Our data demonstrate that free MPO levels are elevated in patients with active
AAN and reduced when disease reaches remission. Renal biopsies of patients
with diverse forms of CGN had extracellular glomerular MPO deposition that
correlated significantly with clinical and histological disease severity. In vitro,
AZM198 led to a significant reduction in neutrophil extracellular trap (NET)
formation, reactive oxygen species (ROS) production and neutrophil
degranulation and attenuated neutrophil-mediated endothelial cell damage. In
vivo, delayed AZM198 treatment at two different doses reduced glomerular
inflammation.
Combining a murine model of chronic glomerular inflammation and atheroma
formation showed that the presence of nephritis enhances atheroma formation.
This model will be used in future work to compare treatment with AZM198 with
corticosteroid therapy, currently used to treat most conditions associated with
CGN.
› More search options
There are no UCL People associated with this publication